Survey on long-term use of AJOVY for migraine treatment
Official title: AJOVY Subcutaneous Injection Long-term Specified Use-results Survey
Run by Otsuka Pharmaceutical Co., Ltd. · NCT05342493 · Data updated 2026-11-12
This study is looking to see how safe AJOVY is for people using it to treat migraines over a long time, especially regarding heart-related issues.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Otsuka Pharmaceutical Co., Ltd. Industry-sponsored |
| Locations | 1 site (Osaka) |
| Status | Recruiting |
| Started | April 20, 2022 |
| Main results expected | September 30, 2026 |
| Study ends | June 22, 2029 |
| Registry record updated | June 22, 2026 |
| Trial ID | NCT05342493 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with migraine disorders who are currently using AJOVY.
✕Probably not a fit
Patients with known hypersensitivity to components of AJOVY will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the long-term safety of AJOVY, a medication for migraine disorders, in real-world settings. It will specifically assess cardiovascular events associated with its use while also collecting information on the drug's efficacy. The study will involve patients who are currently using AJOVY to gather data on its effects over time.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term safety and effectiveness of AJOVY for migraine patients.
How similar studies have gone: Other studies evaluating long-term safety of migraine treatments have shown promising results, suggesting that this approach is relevant and potentially beneficial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Exclusion Criteria: * patients with a known hypersensitivity to components of AJOVY
Where it's running
-
Pharmacovigilance Department
Osaka, Japan Recruiting
Study contacts
- Study coordinator: Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd
- Email: komaniwa.satoshi@otsuka.jp
- Phone: +81-6-6943-7722
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HEADS Registry: Headache, Ear, Auditory, Dizziness, and Sinus</n> Registry
This registry tests whether collecting online symptom reports from adults in the U.S. with sinus, vestibular, ear, or headache symptoms can help improve diagnosis and treatment.
-
MMA Embolization for Migraine: Patient-Reported Outcomes from a Single Site
This registry tests whether adults with migraine who have or plan to have middle meningeal artery embolization notice changes in headaches and quality of life over time.
-
Greater Occipital Nerve Block for Migraine with Medication Overuse Headache
This study will test whether a nerve block using lidocaine and methylprednisolone can help people with migraine who overuse medications to reduce withdrawal headaches during detoxification.
-
Closing a PFO to improve glymphatic function and migraine symptoms
This study will see if closing a patent foramen ovale (PFO) improves glymphatic system function and reduces migraine attacks in adults with PFO and migraine.
-
Italian Migraine Registry (I-GRAINE-NEW)
This registry will collect past and future clinical and healthcare data from adults with episodic or chronic migraine who come to specialized headache centers in Italy to better understand how the condition evolves and is treated.
-
Topical cannabidiol (Canvert-M) for migraine attacks
This will test whether applying Canvert-M, a topical roll-on with cannabidiol and essential oils, can reduce pain during migraine attacks in adults aged 18–55.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.